Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics reported a 14.5% increase in income from ordinary activities for the year ending June 30, 2025, reaching $26.17 million. However, the company also experienced a 33.3% increase in losses, amounting to $50.3 million, and did not declare any dividends. The company increased its equity share in Vision Pharma Limited to 97.1%, indicating a strategic move to consolidate its holdings.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. Utilizing a proprietary drug delivery platform, the company aims to enhance the potency of precision medicines, specifically targeting monogenic diseases, which have a higher likelihood of success in clinical development.
Average Trading Volume: 635,828
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$758.2M
See more insights into PYC stock on TipRanks’ Stock Analysis page.